Literature DB >> 24900482

Targeted kinase selectivity from kinase profiling data.

Francesca Milletti1, Johannes C Hermann2.   

Abstract

Kinase selectivity plays a major role in the design strategy of lead series and in the ultimate success of kinase drug discovery programs. Although profiling compounds against a large panel of protein kinases has become a standard part of modern drug discovery, data accumulated from these kinase panels may be underutilized for new kinase projects. We present a method that can be used to optimize the selectivity profile of a compound using historical kinase profiling data. This method proposes chemical transformations based on pairs of very similar compounds, which are both active against a desired target kinase and differ in activity against another kinase. We show that these transformations are transferable across scaffolds, thus making this tool valuable to exploit kinase profiling data for unrelated series of compounds.

Keywords:  Kinase inhibitors; activity cliffs; computational method; kinase panels; kinase selectivity; matched pairs

Year:  2012        PMID: 24900482      PMCID: PMC4025760          DOI: 10.1021/ml300012r

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

Review 1.  Protein kinase inhibitors: insights into drug design from structure.

Authors:  Martin E M Noble; Jane A Endicott; Louise N Johnson
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

2.  Chemical substitutions that introduce activity cliffs across different compound classes and biological targets.

Authors:  Anne Mai Wassermann; Jürgen Bajorath
Journal:  J Chem Inf Model       Date:  2010-07-26       Impact factor: 4.956

3.  Lead optimization using matched molecular pairs: inclusion of contextual information for enhanced prediction of HERG inhibition, solubility, and lipophilicity.

Authors:  George Papadatos; Muhammad Alkarouri; Valerie J Gillet; Peter Willett; Visakan Kadirkamanathan; Christopher N Luscombe; Gianpaolo Bravi; Nicola J Richmond; Stephen D Pickett; Jameed Hussain; John M Pritchard; Anthony W J Cooper; Simon J F Macdonald
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

4.  Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.

Authors:  Tsung H Lin; Martin Hegen; Elizabeth Quadros; Cheryl L Nickerson-Nutter; Kenneth C Appell; Andrew G Cole; Yuefei Shao; Steve Tam; Michael Ohlmeyer; Bojing Wang; Debra G Goodwin; Earl F Kimble; Jorge Quintero; Min Gao; Peter Symanowicz; Christopher Wrocklage; Jennifer Lussier; Scott H Schelling; Amha G Hewet; Dejun Xuan; Rustem Krykbaev; Jenny Togias; Xin Xu; Richard Harrison; Tarek Mansour; Mary Collins; James D Clark; Maria L Webb; Katherine J Seidl
Journal:  Arthritis Rheum       Date:  2010-08

5.  Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure.

Authors:  Andrew G Leach; Huw D Jones; David A Cosgrove; Peter W Kenny; Linette Ruston; Philip MacFaul; J Matthew Wood; Nicola Colclough; Brian Law
Journal:  J Med Chem       Date:  2006-11-16       Impact factor: 7.446

6.  Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.

Authors:  Lalgudi S Harikrishnan; Muthoni G Kamau; Honghe Wan; Jennifer A Inghrim; Kurt Zimmermann; Xiaopeng Sang; Harold A Mastalerz; Walter L Johnson; Guifen Zhang; Louis J Lombardo; Michael A Poss; George L Trainor; John S Tokarski; Matthew V Lorenzi; Dan You; Marco M Gottardis; Kathy F Baldwin; Jonathan Lippy; David S Nirschl; Ruhui Qiu; Arthur V Miller; Javed Khan; John S Sack; Ashok V Purandare
Journal:  Bioorg Med Chem Lett       Date:  2011-01-11       Impact factor: 2.823

7.  Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.

Authors:  Marc D Jacobs; Paul R Caron; Brian J Hare
Journal:  Proteins       Date:  2008-03

8.  Structure--activity landscape index: identifying and quantifying activity cliffs.

Authors:  Rajarshi Guha; John H Van Drie
Journal:  J Chem Inf Model       Date:  2008-02-28       Impact factor: 4.956

9.  Navigating the kinome.

Authors:  James T Metz; Eric F Johnson; Niru B Soni; Philip J Merta; Lemma Kifle; Philip J Hajduk
Journal:  Nat Chem Biol       Date:  2011-02-20       Impact factor: 15.040

10.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

View more
  4 in total

Review 1.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

2.  Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.

Authors:  Anand Divakaran; Siva K Talluri; Alex M Ayoub; Neeraj K Mishra; Huarui Cui; John C Widen; Norbert Berndt; Jin-Yi Zhu; Angela S Carlson; Joseph J Topczewski; Ernst K Schonbrunn; Daniel A Harki; William C K Pomerantz
Journal:  J Med Chem       Date:  2018-10-16       Impact factor: 7.446

3.  Structure-guided selection of specificity determining positions in the human Kinome.

Authors:  Mark Moll; Paul W Finn; Lydia E Kavraki
Journal:  BMC Genomics       Date:  2016-08-18       Impact factor: 3.969

4.  Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome.

Authors:  Drew H Bryant; Mark Moll; Paul W Finn; Lydia E Kavraki
Journal:  PLoS Comput Biol       Date:  2013-06-06       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.